{
    "clinical_study": {
        "@rank": "87289", 
        "arm_group": {
            "arm_group_label": "NPB-01", 
            "arm_group_type": "Experimental", 
            "description": "Intravenous immunoglobulin"
        }, 
        "brief_summary": {
            "textblock": "Patients diagnosed with Chronic Inflammatory Demyelinating Polyneuropathy were confirmed\n      based on the European Federation of Neurological Societies/ Peripheral. Nerve Society\n      Guideline. Patients who meet all inclusion criteria and do not conflict with the exclusion\n      criteria will receive NPB-01 (intravenous immunoglobulin) 400mg/kg/day for five consecutive\n      days. Subsequently, patients receive NPB-01 1g/kg every 3weeks and evaluate the Inflammatory\n      Neuropathy Cause and Treatment\uff08INCAT\uff09 score and INCAT sensory sumscore\uff08ISS\uff09 et al.\n\n      As a safety endpoint, the safety of NPB-01 will be investigated the occurrence of adverse\n      events by one year after the start of the study treatment."
        }, 
        "brief_title": "Phase III Clinical Trial of NPB-01maintenance Therapy in Patients With Chronic Inflammatory Demyelinating Polyneuropathy.", 
        "completion_date": {
            "#text": "March 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Chronic Inflammatory Demyelinating Polyneuropathy", 
        "condition_browse": {
            "mesh_term": [
                "Polyneuropathies", 
                "Polyradiculoneuropathy, Chronic Inflammatory Demyelinating"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  1. Patients with progressive or relapsing motor and sensory dysfunction of more than\n             one limb resulting from neuropathy within 2 months prior to the date informed consent\n             is obtained.\n\n          -  2. Patients who INCAT score between 2-9. (If the INCAT score is 1 in upper limb, the\n             INCAT score of 2 must be exclusively from leg disability to qualify.)\n\n          -  3. Patients who need high-dose intravenous immunoglobulin therapy.\n\n          -  4. Patients who continued treatment for CIDP without addition or increase at 30 days\n             before informed consent.\n\n          -  5. Patients with greater than or equal to twenty years old at informed consent.\n\n        Exclusion Criteria:\n\n          -  1. Patients with evidence of myelopathy or demyelination of central nerve\n\n          -  2. Patients with evidence of stroke, central nerve system trauma, or persistent\n             neurological deficits due to peripheral neuropathy from other causes\uff08diabetic\n             neuropathy, IgM paraproteinaemia, uraemic neuropathy, toxic neuropathy, hereditary\n             neuropathy\uff09\n\n          -  3. Patients with evidence of neuropathy or alcoholic neuropathy or vitamin deficiency\n             neuropathy due to myeloma, lymphoma, sarcoidosis, systemic lupus erythematosus,\n             malignancy, vasculitis, Crow\u2010Fukase syndrome, Sj\u00f6gren syndrome.\n\n          -  4. Patients with multifocal motor neuropathy.\n\n          -  5. Patients treated with plasmapheresis at 3 months before informed consent.\n\n          -  6. Patients treated with rituximab at 6 months before informed consent.\n\n          -  7. Patients treated with high-dose intravenous immunoglobulin\uff08greater than or equal\n             to 1g/kg\uff09 at 8 weeks before informed consent.\n\n          -  8. Patients treated with intravenous immunoglobulin at 3 weeks before informed\n             consent.\n\n          -  9. Patients with history of shock or hypersensitivity for NPB-01.\n\n          -  10. Patients with IgA deficiency.\n\n          -  11. Patients with malignancy at informed consent.\n\n          -  12. Patients with impaired liver function.\n\n          -  13. Patients with impaired renal function.\n\n          -  14. Patients with cerebro- or cardiovascular disorders.\n\n          -  15. Patients with high risk of thromboembolism.\n\n          -  16. Patients with hemolytic/hemorrhagic anemia.\n\n          -  17. Patients with decreased cardiac function.\n\n          -  18. Patients with decreased platelet."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "20 Years"
        }, 
        "enrollment": {
            "#text": "48", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "April 1, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01824251", 
            "org_study_id": "NPB-01-09/C-01"
        }, 
        "intervention": {
            "arm_group_label": "NPB-01", 
            "intervention_name": "NPB-01", 
            "intervention_type": "Drug", 
            "other_name": "Intravenous immunoglobulin"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Immunoglobulins", 
                "Antibodies", 
                "Immunoglobulins, Intravenous", 
                "Rho(D) Immune Globulin"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "IVIG in Chronic Inflammatory Demyelinating Polyneuropathy", 
            "Patients with Chronic Inflammatory Demyelinating Polyneuropathy"
        ], 
        "lastchanged_date": "July 10, 2013", 
        "location": {
            "contact": {
                "email": "kaihatsu@nihon-pharm.co.jp", 
                "last_name": "Yasumasa Ogawa"
            }, 
            "facility": {
                "address": {
                    "city": "Osaka", 
                    "country": "Japan"
                }, 
                "name": "Nihon Pharmaceutical Co., Ltd"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Japan"
        }, 
        "number_of_arms": "1", 
        "official_title": "NPB-01(Intravenous Immunoglobulin) Maintenance Therapy for Patients With Chronic Inflammatory Demyelinating Polyneuropathy.", 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Japan: Pharmaceuticals and Medical Devices Agency", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "March 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "measure": "proportion of patients with more than 1point improvement in the INCAT score relative to baseline at 28weeks.", 
                "safety_issue": "No", 
                "time_frame": "28weeks"
            }, 
            {
                "measure": "proportion of patients with more than 1point exacerbation in the INCAT score relative to 28weeks at 52weeks.", 
                "safety_issue": "No", 
                "time_frame": "52weeks"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01824251"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "INCAT score", 
                "safety_issue": "No", 
                "time_frame": "1,4,7,10,13,16,19,22,25,28,31,34,37,40,43,46,49,52weeks"
            }, 
            {
                "measure": "ISS", 
                "safety_issue": "No", 
                "time_frame": "1,4,7,10,13,16,19,22,25,28,31,34,37,40,43,46,49,52weeks"
            }, 
            {
                "measure": "maximum grip strength", 
                "safety_issue": "No", 
                "time_frame": "1,4,7,10,13,16,19,22,25,28,31,34,37,40,43,46,49,52weeks"
            }, 
            {
                "measure": "Medical Research Council\uff08MRC\uff09 sum score", 
                "safety_issue": "No", 
                "time_frame": "1,4,7,10,13,16,19,22,25,28,31,34,37,40,43,46,49,52weeks"
            }, 
            {
                "measure": "the amplitude of the compound muscle action potential of the most severely affected motor nerve", 
                "safety_issue": "No", 
                "time_frame": "1,4,28,52weeks"
            }
        ], 
        "source": "Nihon Pharmaceutical Co., Ltd", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Nihon Pharmaceutical Co., Ltd", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "April 2013", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "July 2013"
    }
}